Multicenter, randomized study of the efficacy and safety of intravenous iclaprim in complicated skin and skin structure infections

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 7, 2009, Pages 2834-2840

  Krievins, D ^a   Brandt, R ^b   Hawser, S ^b,c   Hadvary, P ^b   Islam, K ^b,d  

^a PAULS STRADINS CLINICAL UNIVERSITY HOSPITAL   (Latvia)

^b Arpida Ltd   (Switzerland)

^c International Health Management Associates Europe Sàrl   (Switzerland)

^d Ki Consulting AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ICLAPRIM; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; INFECTION; INFESTATION; INJECTION SITE REACTION; INJURY; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; METABOLIC DISORDER; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SKIN DISEASE; SKIN INFECTION; SKIN STRUCTURE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; THORAX DISEASE; TREATMENT DURATION; VASCULAR DISEASE;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PYRIMIDINES; SKIN DISEASES, INFECTIOUS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN; YOUNG ADULT;

EID: 67649969576     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01383-08     Document Type: Article

References (26)

1. Cosgrove, S. E., K. C. Carroll, and T. M. Perl. 2004. Staphylococcus aureus with reduced susceptibility to vancomycin. Clin. Infect. Dis. 39:539-545.
2. Eron, L. J., B. A. Lipsky, D. E. Low, D. Nathwani, A. D. Tice, and G. A. Volturo. 2003. Managing skin and soft tissue infections: expert panel recommendations on key decision points. J. Antimicrob. Chemother. 52(Suppl. 1):i3-i17.
3. The European Antimicrobial Resistance Surveillance System. 2007. EARSS annual report 2006. The European Antimicrobial Resistance Surveillance System, Bilthoven, The Netherlands.
4. Hawser, S., L. Weiss, M. Fischer, D. Gillessen, I. Kompis, and K. Islam. 2002. AR-100, a novel diaminopyrimidine compound: activity against selected gram-positive and gram-negative bacterial pathogens and synergy with other antibiotics, p. 228, abstr F-2019. Abstr. 42nd Intersci. Conf. Antimicrob. Agents Chemother.
5. Hawser, S., S. Lociuro, and K. Islam. 2006. In vitro activity of iclaprim against Staphylococcus aureus, group A and group B streptococci, abstr. CPLA 34. Abstr. Third International Symposium on Resistant Gram-Positive Infections. www.grampositive2008.com/abstracts2006.html.
6. Hawser, S., S. Lociuro, and K. Islam. 2006. Dihydrofolate reductase inhibitors as antibacterial agents. Biochem. Pharmacol. 71:941-948.
7. Jones, M. E., D. Draghi, P. K. Grover, S. Hawser, K. Islam, and D. F. Sahm. 2007. Bactericidal activity and post antibiotic effect of iclaprim (ICL) against Staphylococcus aureus (SA), p. 197, abstr. E-906. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother.
8. Klevens, R. M., M. A. Morrison, J. Nadle, S. Petit, K. Gershman, S. Ray, L. H. Harrison, R. Lynfield, G. Dumyati, J. M. Townes, A. S. Craig, E. R. Zell, G. E. Fosheim, L. K. McDougal, R. B. Carey, and S. K. Fridkin. 2007. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298:1763-1771.
9. Krievens, D., A. Leighton, R. Brandt, P. Hadvary, S. Hawser, D. Gillessen, and K. Islam. 2005. Efficacy and safety of intravenous iclaprim in complicated skin and skin structure infections: results of a phase 2 study, p. 404, abstr. L-1579. Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother.
10. Laue, H., L. Weiss, A. Bernardi, S. Hawser, S. Lociuro, and K. Islam. 2007. In vitro activity of the novel diaminopyrimidine, iclaprim, in combination with folate inhibitors and other antimicrobials with different mechanisms of action. J. Antimicrob. Chemother. 60:1391-1394.
11. Mandell, L. A., R. G. Wunderink, A. Anzueto, J. G. Bartlett, G. D. Campbell, N. C. Dean, S. F. Dowell, T. M. File, Jr., D. M. Musher, M. S. Niederman, A. Torres, and C. G. Whitney. 2007. Infectious Diseases Society of America/ American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 44(Suppl. 2): S27-S72.
12. Micek, S. T. 2007. Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin. Infect. Dis. 45(Suppl. 3):S184-S190.
13. Moran, G. J., A. Krishnadasan, R. J. Gorwitz, G. E. Fosheim, L. K. McDougal, R. B. Carey, D. A. Talan, and Emergency ID Net Study Group. 2006. Methicillinresistant S. aureus infections among patients in the emergency department. N. Engl. J. Med. 355:666-674.
14. Nathwani, D., S. Moitra, J. Dunbar, G. Crosby, G. Peterkin, and P. Davey. 1998. Skin and soft tissue infections: development of a collaborative management plan between community and hospital care. Int. J. Clin. Pract. 52:456-460.
15. Nichols, R. L. 1999. Optimal treatment of complicated skin and skin structure infections. J. Antimicrob. Chemother. 44(Suppl. A):19-23.
16. Peppard, W. J., and C. D. Schuenke. 2008. Iclaprim, a diaminopyrimidine dihydrofolate reductase inhibitor for the potential treatment of antibioticresistant staphylococcal infections. Curr. Opin. Investig. Drugs 9:210-225.
17. Reid, G. E., S. A. Grim, C. A. Aldeza, W. M. Janda, and N. M. Clark. 2007. Rapid development of Acinetobacter baumannii resistance to tigecycline. Pharmacotherapy 27:1198-1201.
18. Robert, J., R. Bismuth, and V. Jarlier. 2006. Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus: a 20 year study in a large French teaching hospital, 1983-2002. J. Antimicrob. Chemother. 57:506-510.
19. Sader, H. S., T. R. Fritsche, and R. N. Jones. 2009. Potency and bactericidal activity of iclaprim against recent clinical gram-positive isolates. Antimicrob. Agents Chemother. 53:2171-2175.
20. Sakoulas, G., R. C. Moellering, Jr., and G. M. Eliopoulos. 2006. Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy. Clin. Infect. Dis. 42(Suppl. 1):S40-S50.
21. Schulte, B., A. Heininger, I. B. Autenrieth, and C. Wolz. 2008. Emergence of increasing linezolid-resistance in enterococci in a post-outbreak situation with vancomycin-resistant Enterococcus faecium. Epidemiol. Infect. 136:1131-1133.
22. Steinkraus, G., R. White, and L. Friedrich. 2007. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycinsusceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J. Antimicrob. Chemother. 60:788-794.
23. Stevens, D. L., A. L. Bisno, H. F. Chambers, E. D. Everett, P. Dellinger, E. J. Goldstein, S. L. Gorbach, J. V. Hirschmann, E. L. Kaplan, J. G. Montoya, and J. C. Wade. 2005. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin. Infect. Dis. 41:1373-1406.
24. Tillotson, G. S., D. C. Draghi, D. F. Sahm, K. M. Tomfohrde, T. Del Fabro, and I. A. Critchley. 2008. Susceptibility of Staphylococcus aureus isolated from skin and wound infections in the United States 2005-07: laboratorybased surveillance study. J. Antimicrob. Chemother. 62:109-115.
25. U.S. Food and Drug Administration. 2008. Code of federal regulations, sections 312.50 and 312.56. Food and Drug Administration, Washington, DC.
26. World Medical Association. 2000. Declaration of Helsinki, revised version of the Edinburgh, Scotland, October 2000 declaration.